<![CDATA[New Phase 3 Data Analysis: Lumateperone Shows Promise for Remission of Major Depressive Disorder]]>
Johnson & Johnson has announced a new analysis of phase 3 data which found lumateperone (Caplyta), in combination with an antidepressant, showed significantly greater remission rates in adults with major depressive disorder (MDD) than placebo plus an …